Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 33,151 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Terminated Phase 4 Interventional Results available

EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries

NCT01919190
View directory record Official record
Conditions
Pain
Interventions
EXPAREL, Placebo
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Winter Park, Florida • Savannah, Georgia • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

NCT00729690
View directory record Official record
Conditions
PAIN
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Asokumar Buvanendran
Other
Eligibility
55 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2Phase 3 Interventional

Carnosine and Cognitive Training in Schizophrenia

NCT02686697
View directory record Official record
Conditions
Schizophrenia
Interventions
L-Carnosine, Placebo, Cognitive Training
Drug · Behavioral
Lead sponsor
Abraham Reichenberg
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2022 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg

NCT02659397
View directory record Official record
Conditions
Hyperlipidemia
Interventions
ETC-1002, Atorvastatin, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Northridge, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111 Administered Intrathecally to Cancer and AIDS Patients With Chronic Pain

NCT00002160
View directory record Official record
Conditions
HIV Infections, Cancer, Pain
Interventions
Ziconotide
Drug
Lead sponsor
Neurex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Huntsville, Alabama • Mobile, Alabama • Northport, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 5, 2026, 5:03 PM EST
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

NCT06022224
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Nov 5, 2026, 5:03 PM EST
Terminated Phase 2 Interventional

Comparison of Sulindac, Aspirin, and Ursodiol in Preventing Colorectal Cancer

NCT00062023
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Acetylsalicylic acid (Aspirin), Sulindac, Ursodiol, Sulindac Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Fish Oil (Omega 3), Immune Function, and Mood

NCT00385723
View directory record Official record
Conditions
Inflammation
Interventions
Omega 3 (Fish Oil) Supplementation, Placebo
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
40 Years to 88 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 20, 2012 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia

NCT03360903
View directory record Official record
Conditions
Anesthesia
Interventions
Placebo, Caffeine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
25 Years to 40 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 4 Interventional Results available

Gabapentin for Postop Pain After SSLF

NCT03123861
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Gabapentin, Placebo oral capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Nov 5, 2026, 5:03 PM EST
Recruiting Not applicable Interventional

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

NCT06953661
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Stellate ganglion block, Sham injection of saline, Ropivacaine, Normal saline
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional

Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction

NCT00714961
View directory record Official record
Conditions
Acute Coronary Syndromes
Interventions
Clopidogrel (SR25990), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
3,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Pomegranate Products for Prevention of Common Cold

NCT00617318
View directory record Official record
Conditions
Influenza, Common Cold, Cough, Headache, Fever
Interventions
Pomegranate, Placebo
Dietary Supplement
Lead sponsor
Texas Heart Institute
Other
Eligibility
21 Years to 49 Years
Enrollment
461 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2008 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1 Interventional

A Cognitive Behavioral Therapy-Based Text Messaging Intervention for Methamphetamine Dependence

NCT01577797
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Text messages
Behavioral
Lead sponsor
New Leaf Treatment Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Lafayette, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 3 Interventional Results available

Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

NCT01968213
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Rucaparib, Placebo
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Female only
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
22
States / cities
Tucson, Arizona • Fullerton, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Nov 5, 2026, 5:03 PM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

NCT06995820
View directory record Official record
Conditions
Healthy
Interventions
AZD1613, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 5, 2026, 5:03 PM EST
Terminated Phase 2 Interventional

Lutein and Alzheimer's Disease Study

NCT00596024
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
lutein/zeaxanthin, placebo
Dietary Supplement
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional

MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe Vulvovaginal Candidiasis

NCT01497223
View directory record Official record
Conditions
Vulvovaginal Candidiasis
Interventions
MGCD290
Drug
Lead sponsor
MethylGene Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Lake Worth, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Nov 5, 2026, 5:03 PM EST
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass

NCT03331146
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Saline, Sodium Nitrite
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users

NCT01759446
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Placebo taken first, Generic H/A taken first, Vycavert taken first, Generic H/A plus i taken first, Generic H/A plus p taken first
Drug
Lead sponsor
Acura Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Nov 5, 2026, 5:03 PM EST
Not listed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

NCT01247246
View directory record Official record
Conditions
Oral Mucositis
Interventions
SCV-07, Placebo
Drug
Lead sponsor
SciClone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
49
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers

NCT02348203
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Aspirin, Laboratory Biomarker Analysis, Placebo Administration, Zileuton
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
2
States / cities
Tucson, Arizona • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Nov 5, 2026, 5:03 PM EST
Completed Phase 1Phase 2 Interventional

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503
View directory record Official record
Conditions
COVID-19
Interventions
JINZHEN Granules for Oral Solution, Placebo
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Nov 5, 2026, 5:03 PM EST
Completed Not applicable Interventional Results available

Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia

NCT02898103
View directory record Official record
Conditions
Postoperative Pain
Interventions
Percutaneous peripheral nerve stimulation, Sham stimulation
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Nov 5, 2026, 5:03 PM EST